The US Food and Drug Administration approvedBoston Scientific’s Ranger drug-coated balloon for the treatment of peripheral artery disease in the superficial femoral artery and proximal popliteal artery.
The company announced on 2 November that it plans to immediately launch Ranger in the US. Ranger earned a CE...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?